The development and benefits of metformin in various diseases
Abstract Metformin has been used for the treatment of type II diabetes mellitus for decades due to its safety, low cost, and outstanding hypoglycemic effect clinically. The mechanisms underlying these benefits are complex and still not fully understood. Inhibition of mitochondrial respiratory-chain complex I is the most described downstream mechanism of metformin, leading to reduced ATP production and activation of AMP-activated protein kinase (AMPK). Meanwhile, many novel targets of metformin have been gradually discovered. In recent years, multiple pre-clinical and clinical studies are committed to extend the indications of metformin in addition to diabetes. Herein, we summarized the benefits of metformin in four types of diseases, including metabolic associated diseases, cancer, aging and age-related diseases, neurological disorders. We comprehensively discussed the pharmacokinetic properties and the mechanisms of action, treatment strategies, the clinical application, the potential risk of metformin in various diseases. This review provides a brief summary of the benefits and concerns of metformin, aiming to interest scientists to consider and explore the common and specific mechanisms and guiding for the further research. Although there have been countless studies of metformin, longitudinal research in each field is still much warranted..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Frontiers of medicine - 17(2023), 3 vom: Juni, Seite 388-431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dong, Ying [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Higher Education Press 2023 |
|---|
| doi: |
10.1007/s11684-023-0998-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144817936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144817936 | ||
| 003 | DE-627 | ||
| 005 | 20240404064437.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11684-023-0998-6 |2 doi | |
| 035 | |a (DE-627)OLC2144817936 | ||
| 035 | |a (DE-He213)s11684-023-0998-6-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Dong, Ying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The development and benefits of metformin in various diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Higher Education Press 2023 | ||
| 520 | |a Abstract Metformin has been used for the treatment of type II diabetes mellitus for decades due to its safety, low cost, and outstanding hypoglycemic effect clinically. The mechanisms underlying these benefits are complex and still not fully understood. Inhibition of mitochondrial respiratory-chain complex I is the most described downstream mechanism of metformin, leading to reduced ATP production and activation of AMP-activated protein kinase (AMPK). Meanwhile, many novel targets of metformin have been gradually discovered. In recent years, multiple pre-clinical and clinical studies are committed to extend the indications of metformin in addition to diabetes. Herein, we summarized the benefits of metformin in four types of diseases, including metabolic associated diseases, cancer, aging and age-related diseases, neurological disorders. We comprehensively discussed the pharmacokinetic properties and the mechanisms of action, treatment strategies, the clinical application, the potential risk of metformin in various diseases. This review provides a brief summary of the benefits and concerns of metformin, aiming to interest scientists to consider and explore the common and specific mechanisms and guiding for the further research. Although there have been countless studies of metformin, longitudinal research in each field is still much warranted. | ||
| 650 | 4 | |a metformin | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a aging | |
| 650 | 4 | |a neurological disorder | |
| 700 | 1 | |a Qi, Yingbei |4 aut | |
| 700 | 1 | |a Jiang, Haowen |4 aut | |
| 700 | 1 | |a Mi, Tian |4 aut | |
| 700 | 1 | |a Zhang, Yunkai |4 aut | |
| 700 | 1 | |a Peng, Chang |4 aut | |
| 700 | 1 | |a Li, Wanchen |4 aut | |
| 700 | 1 | |a Zhang, Yongmei |4 aut | |
| 700 | 1 | |a Zhou, Yubo |4 aut | |
| 700 | 1 | |a Zang, Yi |4 aut | |
| 700 | 1 | |a Li, Jia |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers of medicine |d Higher Education Press, 2011 |g 17(2023), 3 vom: Juni, Seite 388-431 |w (DE-627)671806890 |w (DE-600)2636271-5 |w (DE-576)352909021 |x 2095-0217 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:3 |g month:06 |g pages:388-431 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11684-023-0998-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2018 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 3 |c 06 |h 388-431 | ||